Pulished Date August, 2019
ID: 781
Share on
Share on

Asia Pacific Liver Cancer Therapeutics Market Research Report - Segmented By Type, Therapeutics, End-User and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends and Forecast | 2019 - 2024

Pulished: August, 2019
ID: 781
Pages: 145

APAC Liver Cancer Therapeutics Market Size & Growth (2019 - 2024)

The size of the Liver Cancer Therapeutics Market in the Asia Pacific was worth USD 115.74 million in 2019 and estimated to be growing at a CAGR of 10.05%, to reach USD 186.83 million by 2024. 

Recent advances in the treatment for primary liver cancer might deliver some stimulating pointers mainly in the Asian market where sickness and ethnic characteristics demand assessment.

In the Developing regions, such as East and South-East Asia liver cancer is the third most common tumour and the second primary cause of death. Treatment for liver cancer is reliant on numerous factors such as size, type and age of the tumour and whether cancer has extended outside the liver.

The Asia Pacific characterises as the fastest-growing liver cancer treatment market owing to the rising geriatric populations. This increasing number of liver cancer cases in the Asian countries involves the huge number of drugs for the treatment or prevention of liver cancer and tumours.

Further, growing healthcare expenditure and increasing government initiatives are also augmenting the growth of this market. Huge capital investment is a key restraint hindering the growth of the market.

This research report segmented and sub-segmented into the following categories:

  • By Type: Primary, Secondary and Benign Liver Growths
  • By Therapeutics: Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Targeted Therapy
  • By End-User: Pediatrics and Adults
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

On the basis of therapeutics, the Hepatocellular Carcinoma is the largest segment for therapeutics type due to the high prevalence of this type of liver cancer among people.

Regionally, China is the country in terms of revenue of the market for this region while India and Japan are projected to grow at a high rate in the forecast period.

The Top companies leading in the APAC Liver Cancer Therapeutics Market profiled in this report are Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Type                     

                             5.1.1 Primary    

                             5.1.2 Secondary             

                             5.1.3 Benign Liver growths         

              5.2 By Therapeutics                     

                             5.2.1 Hepatocellular Carcinoma

                             5.2.2 Cholangio carcinoma        

                             5.2.3 Hepatoblastoma  

                             5.2.4 Targeted Therapy

              5.3 By End-Users                          

                             5.3.1 Pediatrics

                             5.3.2 Adults      

6. Geographical Analysis                                         

              6.3 Asia-Pacific               

                             6.1 Introduction             

                             6.2 China           

                             6.3 India            

                             6.4 Japan           

                             6.5 South Korea             

                             6.6 Australia     

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Alnylam Pharmaceuticals Inc.                          

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 ImClone Systems Inc.                          

              9.3 Onyx Pharmaceuticals Inc.                 

              9.4 F. Hoffmann-La Roche Ltd.                

              9.5 Pfizer Inc.                  

              9.6 ArQule Inc.               

              9.7 Jennerex Biotherapeutics Inc.                         

              9.8 Celsion Corp.                          

              9.9 Bayer Schering Pharma AG                

              9.10 4SC AG                    

              9.11 Bristol-Myers Squibb Company                    

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Liver Cancer Diagnostics and Therapeutics Market By Region, From 2019-2024 (USD Million)
  2. Asia-Pacific Liver Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Million)
  3. Asia-Pacific Primary Market By Region, From 2019-2024 (USD Million)
  4. Asia-Pacific Secondary Market By Region, From 2019-2024 (USD Million)
  5. Asia-Pacific Benign Liver growths Market By Region, From 2019-2024 (USD Million)
  6. Asia-Pacific Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2019-2024 (USD Million)
  7. Asia-Pacific Hepatocellular Carcinoma Market By Region, From 2019-2024 (USD Million)
  8. Asia-Pacific Cholangio carcinoma Market By Region, From 2019-2024 (USD Million)
  9. Asia-Pacific Hepatoblastoma Market By Region, From 2019-2024 (USD Million)
  10. Asia-Pacific Targeted Therapy Market By Region, From 2019-2024 (USD Million)
  11. Asia-Pacific Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2019-2024 (USD Million)
  12. Asia-Pacific Pediatrics Market By Region, From 2019-2024 (USD Million)
  13. Asia-Pacific Adults Market By Region, From 2019-2024 (USD Million)
  14. China Liver Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Million)
  15. China Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2019-2024 (USD Million)
  16. China Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2019-2024 (USD Million)
  17. India Liver Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Million)
  18. India Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2019-2024 (USD Million)
  19. India Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2019-2024 (USD Million)
  20. Japan Liver Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Million)
  21. Japan Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2019-2024 (USD Million)
  22. Japan Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2019-2024 (USD Million)
  23. South Korea Liver Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Million)
  24. South Korea Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2019-2024 (USD Million)
  25. South Korea Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2019-2024 (USD Million)
  26. Australia Liver Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Million)
  27. Australia Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2019-2024 (USD Million)
  28. Australia Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2019-2024 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample